Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of mavorixafor in chronic primary autoimmune, idiopathic, or congenital neutropenia
MOH_2025-02-04_013693Phase 3Recruiting
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in neutropenia, Autoimmune neutropenia (AIN), idiopathic neutropenia (CIN) and 1 more comparing Mavorixafor with Placebo (2 arms). Primary endpoint: Infection rate and absolute neutrophil count. Started Nov 2024; status: recruiting.
02
Drugs
mavorixafor
03
Conditions
neutropeniaAutoimmune neutropenia (AIN)idiopathic neutropenia (CIN)congenital agranulocytosis (SCN)
Beyond the preview
Go deeper on MOH_2025-02-04_013693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-04_013693.